I feel like
@Adrian is onto something with that point about power calculations and the change from a feasibility trial to a full trial, but I don't have a good enough understanding of these things, or what is expected, to say for sure. It's too late to find out now, but 'bump' for tomorrow.
I've kept meaning to come back to this. Some quick notes, but I'm not sure I really found anything of interest, and I do not really know how these things are meant to be dealt with.
From the
feasibility protocol:
"The specific objectives aim to inform the design of a full-scale, adequately powered randomised trial. The specific objectives are:
...
7. To use the information above to provide estimates of sample size required for a full-scale RCT."
http://www.bristol.ac.uk/media-library/sites/ccah/migrated/documents/smprotv6final.pdf
"2.
Information collected on suitability of the outcome measures used will enable us to apply for funding for further outcome development."
Feasibility paper:
"In this study, we report on the feasibility and acceptability of recruiting families into a trial involving an alternative intervention (the Lightning Process) for CFS/ME to inform the design of a full-scale, adequately powered RCT comparing LP with LP plus specialist medical care."
I don't see where they said anything about how to make SMILE adequately powered though. They had this?:
"
Data analysis
We recorded the number of potentially eligible participants attending the clinic, the number assessed for eligibility, and the number of eligible patients who consented and were randomized. We compared characteristics of eligible patients who were and were not randomized using appropriate descriptive statistics (that is, mean and standard deviation or median and interquartile range (given as first and third quartile, Q1, Q3) for continuous, and number and percent for categorical variables respectively). As the aim of this study was to assess the feasibility of a future definitive trial, we did not undertake a formal sample size calculation."
https://trialsjournal.biomedcentral.com/articles/10.1186/1745-6215-14-415
SMILE protocol:
"Statistical considerations
Sample size
We used a definition of a clinically important difference
for the SF-36 physical function subscale from three ex-
pert consensus panels for chronic diseases in adults. The
panels conducted a literature search and used the Delphi
technique to reach consensus on the thresholds for change
over time for small, moderate and large clinically important
SF-36 change scores [24]. Consensus was agreed by each
panel that a small clinically important difference would
be 10 as this is the equivalent to two state changes (a
state change is one improvement in one item - the mini-
mum difference between inventories). A moderate improve-
ment was defined as 20 and a large improvement as 30.
To be able to detect a difference between the two
treatment arms of 8 to 10 points on the SF-36 PCS at
six months with 90% power and 1% two-sided alpha, we
have calculated (using STATA) that a total of 32 to 50
participants in each arm for analysis are required. Allow-
ing for 10 to 20% non collection of primary outcome
data at six months, we aim to recruit 80 to 112 partici-
pants to the study."
Then in the SMILE paper they say:
"
Sample size
We used a consensus definition for a small clinically important difference of 10 points on the SF-36-PFS.
32 Thirty two to 50 participants in each arm are required to detect a between-group difference of 8 to 10 points on the SF-36-PFS (SD 10) at 6 months with 90% power and 1% two-sided significance. Allowing for 10% to 20% non-collection of primary outcome data, we aimed to recruit 80 to 112 participants."
http://adc.bmj.com/content/early/2017/09/20/archdischild-2017-313375
So it could be that the feasibility study helped them design an adequately powered trial by giving them a rough idea of drop-out rates, and the feasibility study showing a null result for their original primary outcome, and a 'clinically important difference' for the outcome they swopped to was just a coincidence.